Elizabeth A. Platz, ScD
- Division: Cancer Epidemiology
- School of Medicine (Joint)
Center & Institute Affiliations
- Center for Global Health
- George W. Comstock Center for Public Health Research and Prevention
- Welch Center for Prevention, Epidemiology and Clinical Research
615 N. Wolfe Street
Baltimore, Maryland 21205
ScD, Harvard University, 1995
MPH, Yale University, 1989
Dr. Platz is a cancer epidemiologist, whose research on prostate and colon cancers sits at the interface between epidemiology and basic science. Within prospective cohorts, she studies the association of genetic and epigenetic factors as well as circulating markers of androgenicity, inflammation, and oxidation with prostate cancer incidence and recurrence. For colorectal neoplasia, her work focuses on the metabolic syndrome, growth factors, and inflammation as sequelae of adiposity. She also studies the role of modifiable factors that influence these pathways, such as diet and lifestyle, in relation to the incidence of these diseases and other men’s health concerns. In addition, she studies these factors in association with benign conditions of the prostate and colon, including benign prostatic hyperplasia and adenomatous polyps. She has a long-standing interest uncovering explanations for the notably higher rate of prostate cancer in African-American compared to white men, including racial variation in sex steroid hormones in the in utero milieu and throughout life. Dr. Platz conducts her multidisciplinary work with an eye toward translation; that is, identifying strategies to prevent the development or progression of cancer. These goals have led to her recent research interest in the possible benefits of drugs for other indications, including statin drugs, as well as their underlying mechanisms of action in the prevention of the development and recurrence of prostate cancer. Finally, she dabbles in research that identifies and solves methodologic issues in study design germane to epidemiologic and translational studies on prostate cancer detection, incidence, prognosis, and recurrence.
Honors and Awards
Faculty Innovation Fund
Bernstein Young Investigator's Award
Delta Omega Honorary Society in the Public Health Alpha Chapter
2003 and 2007 AMTRA Award (recognition for advising, mentoring and teaching)
2010 Martin D. Abeloff, MD Scholar in Cancer Prevention (First), Sidney Kimmel Comprehensive Cancer Center (honoring the memory of Dr. Abeloff, late Director of the Cancer Center)
- prostate cancer incidence and recurrence
- benign prostatic hyperplasia
- colorectal cancer
- adenomatous polyps
- sex steroid hormones
- vitamin D
- Platz EA, Drake CG, Wilson KM, Sutcliffe S, Kenfield SA, Mucci LA, Stampfer MJ, Willett WC, Camargo CA Jr, Giovannucci E. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2015 Aug 15;137(4):949-58. doi: 10.1002/ijc.29463. Epub 2015 Feb 27. PubMed PMID: 25648070; PubMed Central PMCID: PMC4478199.
- Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):847-56. doi: 10.1158/1055-9965.EPI-13-1126. Epub 2014 Apr 18. PubMed PMID: 24748218; PubMed Central PMCID: PMC4012292.
- Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013 Oct;3(10):1130-41. PMID: 23779129; PMCID: PMC3797255.
- Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prev Res (Phila). 2015 Aug;8(8):737-42. doi: 10.1158/1940-6207.CAPR-15-0097. Epub 2015 May 19. PubMed PMID: 25990087; PubMed Central PMCID: PMC4526348.
- Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011 Jun;1(1):68-77. PMID: 22140654; PMCID: PMC3227223.
- ARIC Cancer